跳至主要内容
临床试验/NCT00414921
NCT00414921已完成2 期

Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)

University of Cincinnati3 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2003年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
30
试验地点
3
主要终点
change in score on the Conners Abbreviated Symptom Questionnaire for Teachers (ASQ-T)

研究概览

简要总结

The purpose of this study is to evaluate the safety and efficacy of two medications--clonidine and methylphenidate--alone or in combination to treat attention deficit hyperactivity disorder in children ages 4 through 6.

详细描述

Attention deficit hyperactivity disorder (ADHD) is a disease characterized by one or more symptoms of hyperactivity, impulsivity, or inattention that interfere with school, home, work, or social settings. ADHD does not have clear physical signs that can be seen in an x-ray or a lab test. The disorder only can be identified by looking for certain behaviors, which vary from person to person.

This trial will compare the benefits and side effects of two medications--clonidine and methylphenidate (MPH)--used alone or in combination to treat ADHD in children. MPH is approved by the Food and Drug Administration (FDA) for the treatment of ADHD symptoms in children, and clonidine is FDA-approved for the treatment of hypertension in adults. Stimulant medications such as MPH are known to safely and effectively treat many ADHD symptoms. Such medicines, however, do not cure the condition or improve all ADHD symptoms, and the long-term effectiveness of these medications is not well-known.

In this study, participants will be randomly selected to receive one of four treatments: 1) clonidine; 2) MPH; 3) clonidine and MPH; or 4) a placebo (an inactive substance). Participation in the study is about 16 weeks, and includes a baseline screening and 5 evaluation visits to assess attention, hyperactivity, overall improvement and general functioning, medication side effects, blood pressure, pulse, and weight.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
4 Years 至 6 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Child with ADHD
  • Child ages 4 through 6
  • Child attending a structured preschool or daycare

排除标准

  • Presence of a tic disorder of any kind or a known active heart disease for which it would be unsafe to use the study drugs
  • Presence of pervasive developmental disorder, autism, mental retardation, or serious psychiatric illness
  • Child not attending a structured preschool or daycare

研究组 & 干预措施

1

Active Comparator

clonidine

干预措施: clonidine (Drug)

2

Active Comparator

methylphenidate

干预措施: methylphenidate (Drug)

3

Active Comparator

methylphenidate and clonidine

干预措施: clonidine (Drug)

3

Active Comparator

methylphenidate and clonidine

干预措施: methylphenidate (Drug)

4

Placebo Comparator

干预措施: placebo (Other)

结局指标

主要结局

change in score on the Conners Abbreviated Symptom Questionnaire for Teachers (ASQ-T)

时间窗: at 16 weeks

次要结局

  • the ASQ-Parent (ASQ-P) and Child Global Assessment Scales (C-GAS). Adverse events were monitored using AE logs, the Pittsburgh Side Effects Rating Scale, vital signs and electrocardiograms.(at 16 weeks)

研究者

申办方类型
Other

研究点 (3)

Loading locations...

相似试验

Preschool Supplement to Clonidine in ADHD... | 临床试验